• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

多国队列研究:哮喘和重症哮喘患者的死亡率。

Multinational cohort study of mortality in patients with asthma and severe asthma.

机构信息

Medical Informatics, ErasmusMC, Rotterdam, the Netherlands.

Clinical Epidemiology, Aarhus, Denmark.

出版信息

Respir Med. 2020 Apr-May;165:105919. doi: 10.1016/j.rmed.2020.105919. Epub 2020 Mar 2.

DOI:10.1016/j.rmed.2020.105919
PMID:32174450
Abstract

BACKGROUND

Data on the risk of death following an asthma exacerbation are scarce. With this multinational cohort study, we assessed all-cause mortality rates, mortality rates following an exacerbation, and patient characteristics associated with all-cause mortality in asthma.

METHODS

Asthma patients aged ≥18 years and with ≥1 year of follow-up were identified in 5 European electronic databases from the Netherlands, Italy, UK, Denmark and Spain during the study period January 1, 2008-December 31, 2013. Patients with asthma-COPD overlap were excluded. Severe asthma was defined as use of high dose ICS + use of a second controller. Severe asthma exacerbations were defined as emergency department visits, hospitalizations or systemic corticosteroid use, all for reason of asthma.

RESULTS

The cohort consisted of 586,436 asthma patients of which 42,611 patients (7.3%) had severe asthma. The age and sex standardized all-cause mortality rates ranged between databases from 5.2 to 9.5/1000 person-years (PY) in asthma, and between 11.3 and 14.8/1000 PY in severe asthma. The all-cause mortality rate in the first week following a severe asthma exacerbation ranged between 14.1 and 59.9/1000 PY. Mortality rates remained high in the first month following a severe asthma exacerbation and decreased thereafter. Higher age, male gender, comorbidity, smoking, and previous severe asthma exacerbations were associated with mortality.

CONCLUSION

All-cause mortality following a severe exacerbation is high, especially in the first month following the event. Smoking cessation, comorbidity-management and asthma-treatment focusing on the prevention of exacerbations might reduce associated mortality.

摘要

背景

哮喘发作后死亡风险的数据较为匮乏。通过这项多中心队列研究,我们评估了哮喘患者的全因死亡率、哮喘加重后的死亡率以及与哮喘全因死亡相关的患者特征。

方法

在研究期间(2008 年 1 月 1 日至 2013 年 12 月 31 日),我们从荷兰、意大利、英国、丹麦和西班牙的 5 个欧洲电子数据库中确定了年龄≥18 岁且随访时间≥1 年的哮喘患者。排除哮喘-COPD 重叠患者。重度哮喘定义为使用高剂量 ICS 和使用第二种控制器。重度哮喘加重定义为因哮喘而急诊就诊、住院或全身使用皮质类固醇。

结果

该队列包括 586436 例哮喘患者,其中 42611 例(7.3%)患有重度哮喘。标准化后的全因死亡率在哮喘患者中,各数据库之间的范围为 5.2 至 9.5/1000 人年(PY),在重度哮喘患者中为 11.3 至 14.8/1000 PY。重度哮喘加重后第一周的全因死亡率范围为 14.1 至 59.9/1000 PY。重度哮喘加重后第一个月的死亡率仍然较高,此后逐渐下降。年龄较大、男性、合并症、吸烟和既往重度哮喘加重与死亡率相关。

结论

重度哮喘发作后全因死亡率较高,尤其是在事件发生后的第一个月。戒烟、合并症管理和以预防加重为重点的哮喘治疗可能会降低相关死亡率。

相似文献

1
Multinational cohort study of mortality in patients with asthma and severe asthma.多国队列研究:哮喘和重症哮喘患者的死亡率。
Respir Med. 2020 Apr-May;165:105919. doi: 10.1016/j.rmed.2020.105919. Epub 2020 Mar 2.
2
Incidence, risk factors and re-exacerbation rate of severe asthma exacerbations in a multinational, multidatabase pediatric cohort study.在一项多国家、多数据库的儿科队列研究中,严重哮喘恶化的发生率、风险因素和再恶化率。
Pediatr Allergy Immunol. 2020 Jul;31(5):496-505. doi: 10.1111/pai.13237. Epub 2020 Mar 20.
3
The frequency of asthma exacerbations and healthcare utilization in patients with asthma from the UK and USA.来自英国和美国的哮喘患者哮喘急性加重的频率及医疗保健利用情况。
BMC Pulm Med. 2017 Apr 27;17(1):74. doi: 10.1186/s12890-017-0409-3.
4
Real life data on incidence and risk factors of severe asthma exacerbations in children in primary care.基层医疗中儿童重度哮喘急性发作的发病率及风险因素的真实生活数据。
Respir Med. 2016 Oct;119:48-54. doi: 10.1016/j.rmed.2016.08.016. Epub 2016 Aug 23.
5
Risk factors of asthma exacerbation based on asthma severity: a nationwide population-based observational study in South Korea.基于哮喘严重程度的哮喘急性加重危险因素:韩国一项基于全国人群的观察性研究。
BMJ Open. 2018 Mar 22;8(3):e020825. doi: 10.1136/bmjopen-2017-020825.
6
Exacerbations and healthcare resource utilization among COPD patients in a Swedish registry-based nation-wide study.在一项基于瑞典登记的全国性研究中,COPD 患者的恶化和医疗资源利用情况。
BMC Pulm Med. 2018 Jan 25;18(1):17. doi: 10.1186/s12890-018-0573-0.
7
Long-Term Impacts of COVID-19 on Severe Exacerbation and Mortality in Adult Asthma: A Nationwide Population-Based Cohort Study.长期 COVID-19 对成人哮喘严重恶化和死亡率的影响:一项全国性基于人群的队列研究。
J Allergy Clin Immunol Pract. 2024 Jul;12(7):1783-1793.e4. doi: 10.1016/j.jaip.2024.03.035. Epub 2024 Mar 29.
8
Economic impact of severe asthma exacerbations in Spain: multicentre observational study.西班牙重度哮喘恶化的经济影响:多中心观察性研究。
J Asthma. 2021 Feb;58(2):207-212. doi: 10.1080/02770903.2019.1674330. Epub 2019 Oct 17.
9
A nationwide survey of the severity, comorbidity, and mortality of hospitalized patients with asthma in Taiwan.一项关于台湾地区住院哮喘患者严重程度、合并症和死亡率的全国性调查。
Pediatr Neonatol. 2013 Aug;54(4):254-60. doi: 10.1016/j.pedneo.2013.01.017. Epub 2013 Mar 13.
10
Risk Factors for Acute Asthma Exacerbations in Adults With Mild Asthma.轻度哮喘成人急性哮喘加重的危险因素
J Allergy Clin Immunol Pract. 2024 Oct;12(10):2705-2716.e6. doi: 10.1016/j.jaip.2024.05.034. Epub 2024 May 29.

引用本文的文献

1
Predictors of mortality and hospitalised exacerbations in obstructive airway diseases.阻塞性气道疾病死亡率及住院加重的预测因素
ERJ Open Res. 2025 Sep 8;11(5). doi: 10.1183/23120541.01276-2024. eCollection 2025 Sep.
2
Exploring the causal relationship between 25-hydroxyvitamin D and asthma: A bidirectional Mendelian randomization study.探索25-羟基维生素D与哮喘之间的因果关系:一项双向孟德尔随机化研究。
Medicine (Baltimore). 2025 Aug 29;104(35):e44249. doi: 10.1097/MD.0000000000044249.
3
Framework for Exploration of Statistical Heterogeneity in Multi-Database Studies: A Case Study Using EXACOS-CV Studies.
多数据库研究中统计异质性的探索框架:一项使用EXACOS-CV研究的案例分析
Clin Epidemiol. 2025 Jun 14;17:551-565. doi: 10.2147/CLEP.S520168. eCollection 2025.
4
Burden of asthma by severity and exacerbation frequency among adult patients naive to biologic asthma therapy: A Finnish cohort study.初治生物制剂治疗的成年哮喘患者中按严重程度和加重频率划分的哮喘负担:一项芬兰队列研究。
J Allergy Clin Immunol Glob. 2025 Mar 14;4(2):100453. doi: 10.1016/j.jacig.2025.100453. eCollection 2025 May.
5
Efficacy of Biologics in Reducing Exacerbations Requiring Hospitalization or an Emergency Department Visit in Patients with Moderate or Severe, Uncontrolled Asthma.生物制剂在降低中重度、未控制哮喘患者需要住院治疗或急诊就诊的病情加重发生率方面的疗效。
Adv Ther. 2025 Jun;42(6):2679-2689. doi: 10.1007/s12325-025-03184-w. Epub 2025 Apr 22.
6
Association between advanced lung cancer inflammation index and all-cause and cause-specific mortality among asthma patients: a cohort study.哮喘患者中晚期肺癌炎症指数与全因死亡率及特定病因死亡率的关联:一项队列研究
Front Nutr. 2025 Feb 6;12:1519271. doi: 10.3389/fnut.2025.1519271. eCollection 2025.
7
Temporal trends and future projections of incidence rate and mortality for asthma in China: an analysis of the Global Burden of Disease Study 2021.中国哮喘发病率和死亡率的时间趋势及未来预测:基于2021年全球疾病负担研究的分析
Front Med (Lausanne). 2025 Jan 29;12:1529636. doi: 10.3389/fmed.2025.1529636. eCollection 2025.
8
Biologics in severe asthma: a state-of-the-art review.重度哮喘中的生物制剂:最新综述
Eur Respir Rev. 2025 Jan 8;34(175). doi: 10.1183/16000617.0088-2024. Print 2025 Jan.
9
Recent increase in asthma mortality in Brazil: a warning sign for the public health system.巴西近期哮喘死亡率上升:公共卫生系统的一个警示信号。
J Bras Pneumol. 2024 Dec 6;50(5):e20240138. doi: 10.36416/1806-3756/e20240138. eCollection 2024.
10
A Multifaceted Exploration of Status Asthmaticus: A Retrospective Analysis in a Romanian Hospital.重症哮喘的多方面探索:罗马尼亚一家医院的回顾性分析
J Clin Med. 2024 Nov 4;13(21):6615. doi: 10.3390/jcm13216615.